Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT.

CONCLUSIONS: Significantly more patients treated with ezetimibe/simvastatin met prespecified and exploratory dual LDL-C and hs-CRP targets than patients treated with simvastatin alone. Reaching both LDL-C and hs-CRP targets was associated with improved outcomes after multivariable adjustment. Clinical Trial Registration-URL: http://www.clinicaltrials.gov; Unique identifier: NCT00202878. PMID: 26330412 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26330412?dopt=Abstract

Source: Circulation - September 1, 2015 Category: Cardiology Authors: Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E Tags: Circulation Source Type: research